Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 10/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.44 |
| ▸ | HTR1A | P08908 | 3/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6928732 | 0.91 | SLC6A4 (0.49) | SLC6A4SLC6A2SLC6A3HTR1AGBA1 | |
| SCHEMBL6923242 | 0.86 | SLC6A4 (0.43) | SLC6A4SLC6A2SLC6A3HTR1A | |
| SCHEMBL1405196 | 0.84 | SLC6A4 (0.63) | SLC6A4SLC6A2SLC6A3HTR1A | |
| SCHEMBL6922676 | 0.83 | SLC6A4 (0.59) | SLC6A4SLC6A2SLC6A3HTR1AGBA1 | |
| SCHEMBL6926948 | 0.81 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3HTR1ATDP1 | |
| SCHEMBL7526768 | 0.79 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3HTR1AGBA1 | |
| SCHEMBL6930302 | 0.79 | TDP1 (0.45) | SLC6A4SLC6A2SLC6A3TDP1GBA1 | |
| SCHEMBL1705710 | 0.79 | GNAI3 (0.57) | SLC6A4SLC6A2SLC6A3HTR1AGNAI3 | |
| SCHEMBL1405249 | 0.79 | SLC6A4 (0.54) | SLC6A4SLC6A2SLC6A3HTR1A | |
| Sulfuric Acid SCHEMBL1405530 | 0.78 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6518284-B2 | For inhibiting the serotonin and/or noradrenaline reuptake, and are useful as medicaments in disorders in which an increase of levels of those neurotransmitters is necessary | FAES, FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS S.A. (ES) | 2003-02-11 | — | — | US | claimed |
| US-20020038031-A1 | New 4 - substituted piperidines | ORJALES VENERO AURELIO (ES) | 2002-03-28 | — | — | US | claimed |
| EP-1002794-A1 | 4-[(Aryl)(aryloxy)methyl]piperidine derivatives and their use as serotonin and/or noradrenaline reuptake inhibitors | FAES, Fabrica Espanola de Productos Quimicos y Farmaceuticos, S.A. (ES) | 2000-05-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020038031-A1 | New 4 - substituted piperidines | ADRA2C, ADRB2, ADRB1 | SLC6A4 11/4885SLC6A2 12/4885SLC6A3 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.